Unknown

Dataset Information

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.


ABSTRACT: SARS-CoV-2 infection causes COVID-19, which frequently leads to clinical deterioration and/or long-lasting morbidity. Academic and governmental experts throughout the USA met in 2021 to discuss the potential for use of fluvoxamine as early treatment of SARS-CoV-2 infection. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that is a strong sigma-1 receptor agonist, and this may effectively reduce cytokine production, preventing clinical deterioration. This repurposed psychiatric medication has a well-known safety record, is inexpensive, easy to use, and widely available, all of which are advantages during this global COVID-19 pandemic. At the meeting, experts reviewed the existing published literature on the use of fluvoxamine as experimental COVID-19 treatment, as well as pri

SUBMITTER: Facente SN 

PROVIDER: S-EPMC8633915 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature